Supplements

St John’s wort: depression evidence, extract differences, conflicting trials, enzyme induction, serious medicine interactions, and long-term uncertainty

6 sources · Latest source check 2026-10-13 UTC

On this page

St John’s wort, Hypericum perforatum, is a plant commonly promoted for depression. Selected studies support some short-term benefit in mild or moderate depression, but results differ. Its established medicine interactions can be serious. A potential benefit does not make it suitable for unsupervised substitution or combination with antidepressants.[1]

Preparation terms describe different compounds

Preparation terms describe different compounds
Term	Meaning
Hypericum perforatum	The plant species.[1]
Hypericin	One chemical constituent.[4]
Hyperforin	A constituent relevant to enzyme induction.[4]
Extract code	Identification of a specific tested preparation.[2]

Similar average results do not make every treatment interchangeable

The review found no significant effectiveness difference from antidepressants in mild or moderate depression, with fewer reported adverse events. Severe depression was less studied, harms reporting was incomplete and trials were not designed to detect rare events. Those limits prevent a blanket claim that every extract is equally effective or safer for every patient.[2]

A review’s publication year differs from its search cutoff

This review searched through November 2014. Its findings describe that study set, rather than all evidence published through 2026. Extract composition and head-to-head comparisons also matter. The selected abstract and methods were inspected here; a complete contemporary review, full product-equivalence analysis and independent trial-level appraisal remain unfinished.[2]

An active-comparator failure limits the interpretation

Because sertraline also failed to separate from placebo on the primary outcomes, the result does not establish equivalent effectiveness between the herb and a proven antidepressant across other settings. Trial sensitivity, population and endpoint choice matter. “No significant difference” is not a demonstration of equivalence, and a single study cannot settle every extract or severity.[3]

The herb can change how the body handles other medicines

Nicolussi and colleagues describe activation of the pregnane X receptor and increased activity of enzymes such as CYP3A4 and the transport protein P-glycoprotein. These processes can alter a drug’s concentration and effectiveness. This is a pharmacokinetic interaction, involving drug handling, rather than simply another side effect such as stomach upset.[4]

Hyperforin content matters, but a reassuring label is insufficient

The review links enzyme induction to hyperforin content and explains that extraction changes chemical composition. A hypericin percentage does not fully describe that interaction risk. A low-hyperforin claim requires verification of the actual product, exposure and medicines; it should not be read as a guarantee that an individual combination is safe.[4]

Commercial context is relevant when reading preparation claims

Three review authors listed affiliations with Max Zeller Söhne AG. That context is disclosed rather than treated as proof that their findings are wrong. Complete independence, sponsor-role and product-specific appraisal were not completed here.[4]

Interactions can undermine essential treatment

NCCIH lists potential weakening of medicines including hormonal contraception, cyclosporine, some HIV and cancer drugs, and warfarin. Combining the herb with serotonin-affecting medicines can also produce serious effects. The entire medication list matters; checking only whether someone takes an antidepressant is insufficient.[1]

Sun sensitivity and reproductive safety also need context

NCCIH describes digestive, sleep-related and skin effects, including increased sensitivity to sunlight. Pregnancy and breastfeeding bring additional concerns. Those questions cannot be answered by a trial’s average antidepressant response or an extract’s long history of use.[1]

Depression severity and care are separate from product choice

NCCIH’s in-depth explanation cautions against replacing conventional care or delaying assessment. Depression can affect function and become severe; professional evaluation considers symptoms, suicide risk and other psychiatric conditions. An educational summary of a supplement cannot establish the diagnosis, select treatment or make an antidepressant-switching plan.[5]

European medicinal categories are preparation-specific

EMA’s monograph separates specified extracts for mild-to-moderate depressive episodes from traditional-use preparations for other named purposes, such as temporary mental exhaustion. Tea, tincture and topical use are not automatically equivalent to the studied oral extracts. The monograph also distinguishes interaction precautions by preparation and hyperforin exposure. These categories do not authorize self-diagnosis or make every retail product with the same plant name interchangeable.[6]

Evidence & uncertainty

NCCIH distinguishes possible mild-to-moderate depression benefit from uncertainty in severe illness and longer treatment. The benefit question and the interaction question must be assessed separately: fewer common side effects in a trial do not mean absence of dangerous effects when the herb is combined with another medicine.[1]

Selected-source overview · Independent review pending

Published questions

Does St John’s wort have the same evidence for every depression severity and duration?

Selected-source overview · Independent review pending. Read the evidence context.

Severe and longer-term illness are less certain.[1]

Evidence behind this answer

St. John’s Wort: Usefulness and Safety
agency condition or prevention explanation · Date not stated
Original indexed official page passages inspected · Plant identity, purpose-specific evidence, serious interactions and other safety concerns